Q-omics provides the consensus-scored ADRA2C profile across patient tissues and cancer cell-line models. ADRA2C expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ADRA2C is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, ADRA2C RNA expression shows 13,928 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KIRC, and GBM as cancer lineages where ADRA2C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADRA2C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADRA2C survival associations across molecular data types. ADRA2C RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADRA2C RNA expression–survival associations across cancer types. High ADRA2C expression shows unfavorable associations in LUAD, ACC and KIRP, but favorable associations in UVM, CHOL and READ. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ADRA2C RNA expression.
This table summarizes ADRA2C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ADRA2C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADRA2C shows lower tumor expression in KIRC, KICH, LUAD and KIRP and higher tumor expression in COAD and LIHC. The KIRC box plot shows higher ADRA2C RNA expression in normal versus tumor tissue (log2 FC = −1.981, t-test p < 0.001).
This table shows molecular features associated with ADRA2C in patient tissues and cancer cell lines. In patient samples, ADRA2C shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ADRA2C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SOFT_TISSUE.
